Featured Stories
When Every Breath Counts: Pulmonology at Sheba Medical Center
RAMAT GAN, Israel, Nov. 7 -- Sheba Medical Center issued the following news:
* * *
When Every Breath Counts: Pulmonology at Sheba Medical Center
November 5, 2026
Two dedicated units at Sheba Medical Center treat patients of all ages living with lung-related diagnoses: the Institute of Pulmonology, Physiology and Exercise, led by Prof. Amir Onn, and the Pediatric Pulmonology Unit, headed by Prof. Ori Efrati and home to Israel's National Cystic Fibrosis Center.
Sheba's pulmonology teams specialize in conditions ranging from asthma and COPD to lung cancer, while its lung transplant unit, established
... Show Full Article
RAMAT GAN, Israel, Nov. 7 -- Sheba Medical Center issued the following news:
* * *
When Every Breath Counts: Pulmonology at Sheba Medical Center
November 5, 2026
Two dedicated units at Sheba Medical Center treat patients of all ages living with lung-related diagnoses: the Institute of Pulmonology, Physiology and Exercise, led by Prof. Amir Onn, and the Pediatric Pulmonology Unit, headed by Prof. Ori Efrati and home to Israel's National Cystic Fibrosis Center.
Sheba's pulmonology teams specialize in conditions ranging from asthma and COPD to lung cancer, while its lung transplant unit, establishedin 2020, has already performed more than 100 transplants and now carries out about one-third of all lung transplants in Israel. Together, this expertise has earned Sheba a place among the leading pulmonology institutions worldwide in Newsweek and Statista's World's Best Specialized Hospitals 2027 ranking.
Most people never have to consciously think about breathing, but pulmonary disorders can turn it into a constant effort. For children and adults alike, that burden impacts school, work, sleep, and time with family.
Personalized Care for Adult Lung Disease
Helping adults manage lung disease at every stage is the core mission of the Institute of Pulmonology, Physiology and Exercise, which treats asthma, COPD, lung cancer, tuberculosis, interstitial lung diseases, pulmonary hypertension, and rare conditions such as alveolar proteinosis. Here, advanced pathology testing supports fast, precise diagnosis, and the spectrum of treatment options includes targeted biologic therapies, immunotherapy, and chemotherapy.
Research at the institute, including Prof. Onn's work on exhaled breath analysis, continues to explore new ways to monitor how late-stage lung cancer responds to medication. Rehabilitation programs help those recovering from illness or surgery regain strength through aerobic and respiratory muscle training, and when other approaches have been exhausted, Sheba's experienced program guides complex cases through the transplant process.
Specialized Support for Growing Lungs
Because young lungs are still developing, treating the conditions affecting them requires a distinct skill set. The multidisciplinary specialists at Sheba's Pediatric Pulmonology Unit, located within the Edmond and Lily Safra Children's Hospital, see about 2,000 patients each year. Those receiving care here range from newborns with bronchopulmonary dysplasia and preschoolers with asthma to adolescents with uncommon disorders such as ataxia telangiectasia. The Unit's National Cystic Fibrosis Center, the largest of its kind in Israel, supports young patients with CF from diagnosis through follow-up after lung transplantation.
Continuity at Every Age
Many chronic lung conditions stay with patients well beyond childhood. With two units at the same medical center providing comprehensive care, young patients can continue treatment at Sheba as they grow. Throughout their journey, psychological support and rehabilitation are available to address how lung disease affects daily life, not only how it affects the lungs. For families and referring physicians seeking more information about the expertise behind Sheba's international accolades, the first step is a consultation request.
* * *
Original text here: https://www.shebaonline.org/when-every-breath-counts-pulmonology-at-sheba/
[Category: BizHospital]
Ropes and Gray: Patricia Lynch Explains in 9fin How Lawyers Help Structure Whole-business Securitizations to Survive Downturns
BOSTON, Massachusetts, Nov. 7 -- Ropes and Gray, a law firm, issued the following news:
* * *
Patricia Lynch Explains in 9fin How Lawyers Help Structure Whole-business Securitizations to Survive Downturns
November 6, 2026
Patricia Lynch, who leads the firm's U.S. securitization practice, explained in a 9fin article how lawyers can help ensure that a whole-business securitization can continue functioning if the parent company that set up the securitization files for bankruptcy.
"If it's a franchise business, you need someone to negotiate new agreements with new franchisees," said Patricia Lynch,
... Show Full Article
BOSTON, Massachusetts, Nov. 7 -- Ropes and Gray, a law firm, issued the following news:
* * *
Patricia Lynch Explains in 9fin How Lawyers Help Structure Whole-business Securitizations to Survive Downturns
November 6, 2026
Patricia Lynch, who leads the firm's U.S. securitization practice, explained in a 9fin article how lawyers can help ensure that a whole-business securitization can continue functioning if the parent company that set up the securitization files for bankruptcy.
"If it's a franchise business, you need someone to negotiate new agreements with new franchisees," said Patricia Lynch,an attorney with Ropes & Gray. "And so, on the legal side, we help the issuers and the bankers think about what mechanisms can be put in place to ensure that there is continuity of those services to defend against a potential bankruptcy at the level of the operating company."
* * *
Original text here: https://www.ropesgray.com/en/news-and-events/news/2026/11/patricia-lynch-explains-in-9fin-how-lawyers-help-structure-whole-business-securitizations
[Category: BizLaw/Legal]
Mayer Brown Advises CTF Holdings on Sale of Rosewood London Hotel to Gencom
CHICAGO, Illinois, Nov. 7 -- Mayer Brown, a law firm, issued the following news:
* * *
06 November 2026
Mayer Brown Advises CTF Holdings on Sale of Rosewood London Hotel to Gencom
London - Mayer Brown has advised Hotel Property Investments (B.V.I.) Ltd and the wider CTF Holdings group on the sale of the Rosewood London hotel to Gencom. Located in the heart of central London, the 308-key Rosewood London is an iconic luxury hotel and one of the capital's most prestigious hospitality assets.
The Mayer Brown team was led by Corporate partner Alastair Dolman in London and included Corporate counsel
... Show Full Article
CHICAGO, Illinois, Nov. 7 -- Mayer Brown, a law firm, issued the following news:
* * *
06 November 2026
Mayer Brown Advises CTF Holdings on Sale of Rosewood London Hotel to Gencom
London - Mayer Brown has advised Hotel Property Investments (B.V.I.) Ltd and the wider CTF Holdings group on the sale of the Rosewood London hotel to Gencom. Located in the heart of central London, the 308-key Rosewood London is an iconic luxury hotel and one of the capital's most prestigious hospitality assets.
The Mayer Brown team was led by Corporate partner Alastair Dolman in London and included Corporate counselDaniel Williams, senior associate Alex Potten and associates Niki Mehta and Alex Bicknell-Cummins, Real Estate Finance partner Andrew Hepner and senior associate Annabel Ersser, Tax partner Ben Eaton and senior associates Kathryn Buddington and Tamar Ruiz, Environmental partner Tim Baines, Real Estate counsel Danielle Blass and associate Rona Ankrah, Construction counsel Charles Pacey and associate George Frake, Employment partners Chris Fisher and Miriam Bruce, counsel James Perrott and associate Jasmin Curme, Pensions partner Andrew Block, Intellectual Property partner Oliver Yaros and associate Rebecca Keay, and Legal Project Management Associate Director Candace Brown and Analyst Chloe Sallaku.
* * *
URL: CTF Holdings
* * *
Original text here: https://www.mayerbrown.com/en/news/2026/11/mayer-brown-advises-ctf-holdings-on-sale-of-rosewood-london-hotel-to-gencom
[Category: BizLaw/Legal]
In the ABA Journal, Howard Glazer and Josh Lichtenstein Discuss Ropes & Gray's AI Partnerships With Leading Tech Providers
BOSTON, Massachusetts, Nov. 7 -- Ropes and Gray, a law firm, issued the following news:
* * *
In the ABA Journal, Howard Glazer and Josh Lichtenstein Discuss Ropes & Gray's AI Partnerships with Leading Tech Providers
November 6, 2026
Howard Glazer, head of practice AI and co-head of Ropes & Gray's global private equity transactions practice, and Josh Lichtenstein, head of the firm's ERISA fiduciary practice and a leader of its AI development efforts, were quoted in an article published in the ABA Journal about how large law firms are partnering with major tech companies to build custom AI tools.
The
... Show Full Article
BOSTON, Massachusetts, Nov. 7 -- Ropes and Gray, a law firm, issued the following news:
* * *
In the ABA Journal, Howard Glazer and Josh Lichtenstein Discuss Ropes & Gray's AI Partnerships with Leading Tech Providers
November 6, 2026
Howard Glazer, head of practice AI and co-head of Ropes & Gray's global private equity transactions practice, and Josh Lichtenstein, head of the firm's ERISA fiduciary practice and a leader of its AI development efforts, were quoted in an article published in the ABA Journal about how large law firms are partnering with major tech companies to build custom AI tools.
Thearticle highlights the AI-powered diligence tool Ropes & Gray developed with OpenAI ahead of the launch of Astra for Law. The tool follows the steps the firm's attorneys take when reviewing large volumes of documents and produces a comprehensive diligence report in just hours.
Josh said the tool, which is in testing, is consistently producing better results than off-the-shelf diligence applications. "What the process looked like for us was a combination of the engineering expertise from OpenAI plus our own vision as lawyers of how a tool should work," he said.
Howard noted that the firm also speaks regularly with other leading tech providers. "We will talk to anyone," he said. "As a firm, we are total believers that AI will transform the industry, and so we are intent on being at the front of the wave." He also pointed to the firm's partnership with Draftwise to deploy a legal ontology platform in its private funds practice. "Our partnerships with OpenAI and Draftwise tie back to our broader AI strategy--building AI around our clients' needs and our relationships with them, and using that knowledge to amplify our lawyers' judgment," he said.
* * *
Original text here: https://www.ropesgray.com/en/news-and-events/news/2026/11/howard-glazer-and-josh-lichtenstein-discuss-ropes-grays-ai-partnerships-with-leading-tech-providers
[Category: BizLaw/Legal]
Hooper, Lundy and Bookman: DEA Opens Path for Direct-to-Provider Delivery of Certain Controlled Substances
LOS ANGELES, California, Nov. 7 -- Hooper, Lundy and Bookman, a law firm, issued the following news:
* * *
DEA Opens Path for Direct-to-Provider Delivery of Certain Controlled Substances
11.06.26
Last week, the U.S. Drug Enforcement Agency ("DEA") issued non-binding guidance permitting a DEA-registered pharmacy to deliver certain controlled substances directly to an administering practitioner acting under the ultimate user's "power of attorney" ("POA").
This new pathway could ease logistical burdens for patients and providers, while facilitating more controlled handling of certain controlled
... Show Full Article
LOS ANGELES, California, Nov. 7 -- Hooper, Lundy and Bookman, a law firm, issued the following news:
* * *
DEA Opens Path for Direct-to-Provider Delivery of Certain Controlled Substances
11.06.26
Last week, the U.S. Drug Enforcement Agency ("DEA") issued non-binding guidance permitting a DEA-registered pharmacy to deliver certain controlled substances directly to an administering practitioner acting under the ultimate user's "power of attorney" ("POA").
This new pathway could ease logistical burdens for patients and providers, while facilitating more controlled handling of certain controlledsubstances and their safe delivery to a health care setting for administration. Providers and pharmacies should be mindful, however, that power of attorney requirements vary by state. Beyond these state-specific requirements, providers and pharmacies should consider incorporating appropriate safeguards and procedures to support compliant use of direct-to-provider delivery.
What has changed?
The Controlled Substances Act ("CSA") requires that a DEA-registered pharmacy dispense a prescribed controlled substance directly to the "ultimate user," typically the patient for whom the controlled substance is prescribed. 21 U.S.C. Sec. 802(10) & (27).
The DEA has now clarified an additional pathway for satisfying this requirement when a prescribed controlled substance is delivered directly to an administering practitioner. Pursuant to the new guidance, the ultimate user may use a POA to designate the administering practitioner (e.g., a physician, hospital, etc., defined in 21 U.S.C. Sec. 802(21)) as the ultimate user's agent for the limited purpose of accepting delivery of the prescribed controlled substance. Under this arrangement, the practitioner receives the controlled substance as the ultimate user's agent, rather than in the practitioner's capacity as a DEA registrant. The DEA states that the pathway is only available for controlled substances that either must, pursuant to FDA requirements, or should, for quality control or other reasons, be delivered to the administering practitioner for administration in a health care setting.
The CSA already permits the delivery of a Schedule III-V controlled substance to an administering practitioner--but only if the controlled substance is (1) administered by injection or implantation for the purpose of maintenance or detoxification treatment or (2) subject to a REMS (risk evaluation and mitigation strategy) with ETASU (elements to assure safe use), and other conditions are met. 21 U.S.C. Sec. 829a. The new guidance preserves those existing statutory pathways but provides an additional POA-based pathway that is not expressly limited to Schedule III-V controlled substances. Accordingly, the new pathway may also be available for Schedule II controlled substances that satisfy the guidance's criteria.
Why is this important?
The CSA's strict delivery requirements serve as important safeguards against diversion. But they create logistical challenges for patients prescribed controlled substances, especially when patients need to transport sensitive products to a health care setting for administration. Those logistical burdens are exacerbated--and the risk for mishandling increased--for controlled substances that must be maintained at particular temperatures or that require careful handling. Direct delivery to the practitioner could help to minimize these logistical burdens, maintain controlled storage of these products, and reduce the risk of theft or diversion.
What does this mean for practitioners and pharmacies?
Administering Practitioners: The DEA guidance does not establish parameters for a qualifying POA beyond requiring that it comply with state law. Administering practitioners should engage legal counsel to ensure that the POA satisfies applicable state law requirements and to determine the appropriate retention period for the POA records.
Administering practitioners should also implement procedures to keep controlled substances received pursuant to a POA separate from controlled substances held under the practitioner's DEA registration. Because the practitioner receives the medication as the patient's agent rather than as a DEA registrant, providers should also develop procedures for handling unwanted or waste medication consistent with DEA's ultimate-user disposal requirements. Practitioners must comply with all other applicable requirements of the CSA and its implementing regulations governing prescribing, handling, and administering controlled substances.
Pharmacies: The DEA guidance reiterates that DEA-registered pharmacies must continue to comply with all CSA and DEA regulatory requirements, including those related to proper dispensing of valid prescriptions. To use this new POA pathway, DEA pharmacies must maintain records that document direct-to-provider delivery, including the practitioner's name and the address to which the controlled substance was delivered. Pharmacies should consult legal counsel to understand state-specific POA requirements and applicable record-retention periods and establish procedures for verifying the existence and validity of the POA prior to dispensing.
* * *
Hooper Lundy & Bookman can assist practitioners and pharmacies in developing and implementing policies and procedures to ensure compliant use of this new delivery pathway. For more information or assistance, please reach out to Caitlin Callahan, Alicia Macklin, Nina Marsden, or your regular Hooper, Lundy & Bookman contact.
* * *
Original text here: https://hooperlundy.com/dea-opens-path-for-direct-to-provider-delivery-of-certain-controlled-substances/
[Category: BizLaw/Legal]
Herbert Smith Freehills Kramer is Advising Schneider Electric on the Issuance of Six Bond Issues of 6 Billion Euros as Part of the Financing of the Acquisition of PTC Inc.
NEW YORK, Nov. 7 -- Herbert Smith Freehills Kramer LLP, a law firm, issued the following news:
* * *
Herbert Smith Freehills Kramer is advising Schneider Electric on the issuance of six bond issues of 6 billion euros as part of the financing of the acquisition of PTC Inc.
November 5, 2026
Herbert Smith Freehills Kramer advised Schneider Electric, a global leader in energy technologies, on its issuance of six senior bond issues totaling Euros6 billion under its EMTN program.
The issue, comprising six tranches maturing between 2028 and 2046, is part of the financing for the announced acquisition
... Show Full Article
NEW YORK, Nov. 7 -- Herbert Smith Freehills Kramer LLP, a law firm, issued the following news:
* * *
Herbert Smith Freehills Kramer is advising Schneider Electric on the issuance of six bond issues of 6 billion euros as part of the financing of the acquisition of PTC Inc.
November 5, 2026
Herbert Smith Freehills Kramer advised Schneider Electric, a global leader in energy technologies, on its issuance of six senior bond issues totaling Euros6 billion under its EMTN program.
The issue, comprising six tranches maturing between 2028 and 2046, is part of the financing for the announced acquisitionof PTC Inc. and follows Schneider Electric's Euros6 billion capital increase in October 2026.
This will reduce the bridge loan facility established by Schneider Electric when the acquisition was announced to secure financing, covering the cash consideration for the acquisition of approximately Euros22 billion. The Herbert Smith Freehills Kramer team advising on this issuance is the same team that advised Schneider Electric on the establishment of this facility. This transaction thus illustrates our team's ability to handle, in an integrated manner, the various banking and bond aspects of a single strategic transaction, by mobilizing a single team across the entire financing structure.
The Herbert Smith Freehills Kramer team consisted of Louis de Longeaux, partner, and Sophie Lesdos, associate.
The banks were advised by A&O Shearman, with a team consisting of Julien Sebastien, partner, Lorraine Mirramond, counsel, Marion Hebrard-Lemaire, Hakima Gourari and Aziz Ben Hamida, associates, in Paris.
* * *
URL: Schneider Electric
* * *
Original text here: https://www.hsfkramer.com/news/2026-11/hsf-kramer-conseille-schneider-electric
[Category: BizLaw/Legal]
A&O Shearman Advises Lenders on Phoenix Tower International's USD6.5 Billion Multi-jurisdiction Financing
LONDON, England, Nov. 7 -- A&O Shearman, a law firm, issued the following news:
* * *
A&O Shearman advises lenders on Phoenix Tower International's USD6.5 billion multi-jurisdiction financing
Nov 6, 2026
A&O Shearman has advised the lenders on Phoenix Tower International's (PTI) USD6.5bn multi-jurisdiction financing, one of the largest tower infrastructure financings in recent years.
The transaction reflects the continued growth and strategic ambition of PTI, a leading independent telecommunications infrastructure group with operations across the United States, Latin America, the Caribbean
... Show Full Article
LONDON, England, Nov. 7 -- A&O Shearman, a law firm, issued the following news:
* * *
A&O Shearman advises lenders on Phoenix Tower International's USD6.5 billion multi-jurisdiction financing
Nov 6, 2026
A&O Shearman has advised the lenders on Phoenix Tower International's (PTI) USD6.5bn multi-jurisdiction financing, one of the largest tower infrastructure financings in recent years.
The transaction reflects the continued growth and strategic ambition of PTI, a leading independent telecommunications infrastructure group with operations across the United States, Latin America, the Caribbeanand Europe. It comprises USD5.365bn equivalent term loan facilities, USD635m equivalent delayed draw term loan facilities and a USD500m revolving credit facility, and spans all of PTI's 23 jurisdictions. The financing consolidates PTI's existing loans, on which A&O Shearman had also advised the relevant lenders, and provides significant additional capacity to support PTI's ongoing expansion and infrastructure investment across its global portfolio.
* * *
"We are delighted to have advised the lenders on this landmark financing for Phoenix Tower International. Its sophisticated capital structure, scale and execution across multiple jurisdictions make it a particularly significant transaction in the global infrastructure market. It is exactly the type of complex, cross-border infrastructure financing that our integrated global finance and tax platform is designed to deliver."
- Annette Kurdian, Partner
* * *
A&O Shearman's team was led by London-based partner Annette Kurdian, alongside James Ashcroft (London), Todd Koretzky (New York), Driss Bererhi (Paris), Jimena Urretavizcaya (Madrid) and Esther Lemmon (London, tax), together with senior associates Jeane Benny, Leonie Adam, Ruby-Jane van Zyl, Diogo Casqueiro, Dimitar Grozdanov, Dorian Le, Nuria Ferre and Eunjee Chae. Finance and tax teams across London, New York, Paris, Madrid, Frankfurt and Milan provided support, underscoring the firm's ability to execute highly complex, multi-jurisdictional infrastructure financings seamlessly across its global platform.
* * *
URL: Phoenix Tower International
* * *
Original text here: https://www.aoshearman.com/en/news/ao-shearman-advises-lenders-on-phoenix-tower-internationals-usd6-5-b
[Category: BizLaw/Legal]
